New hope for recurrent endometrial cancer: GSK5733584 faces chemo in major trial
NCT ID NCT07286331
First seen Jan 10, 2026 · Last updated May 08, 2026 · Updated 20 times
Summary
This phase 3 study tests a new drug, GSK5733584, against standard chemotherapy for people whose endometrial cancer has come back or persists. About 600 adults with recurrent endometrial cancer will be randomly assigned to receive either the new drug or chemotherapy. The goal is to see which treatment works better at shrinking tumors and delaying cancer growth, while also checking safety and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS, ENDOMETRIAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.